What it does
The group says its investments are those that its directors have identified as “having significant upside” for the company.
What it owns
- The Diabetic Boot Company – Firm focused on the treatment of diabetic foot ulcers through its PulseFlow diabetic-friendly footwear
- Factom – Blockchain company using the technology to simplify records management, record business processes and address security and compliance issues
- Vemo Education – Education technology company that looks to solve student debt problems by developing income share agreement programmes and deferred tuition plans
- Leap Gaming – Developer and provider of 3D gaming technology and products with a focus on virtual sports and virtual casino
- Juvenescence – Therapeutics and development company focusing on improving and extending human lifespans
- Emmac – Company focused on the production and supply of medicinal cannabis, hemp and other derivative products
- Portage Biotech – Works to enable research & development to produce clinical programs for a variety of cancers by providing funding, strategic business and clinical counsel, and shared services
- Yooma – Hemp-based wellness products firm planning to partner with some of Pan-Asia’s leading social and e-commerce platforms to create the first hemp and cannabidiol (CBD) lifestyle company in Asia
- Little Green Pharma (0.9% stake) – medicinal cannabis oil products supplier
How it is doing
FastForward reported growth in the value of its net assets in the first half of its current year.
For the six months to September 30, the AIM-listed group reported a net asset value (NAV) of 9.43p per share, up from 8.82p at the end of March, while total investment gains for the half-year stood at £1.46mln.
The improvement in NAV was attributed party to the company’s investment in Yooma Corp, Asia’s first HEMP and CBD lifestyle company, as well as reported continued growth in fellow investee Leap Gaming.
The shares virtually doubled between November and February on a series of positive announcements concerning the companies in which it has invested, the latest of which was Little Green Pharma (LGP), where it has a 0.9% interest.
LGP has announced it will exclusively supply medicinal cannabis oil products to enrolled patients in the QUality of life Evaluation Study, commonly known as The QUEST Initiative. The study investigates to what extent patients with a chronic disease have their quality of life improved by medicinal cannabis products.
What the boss says: Ian Burns, chairman
“We have a solid track record in the medical cannabis space and are confident that with the recent guidance from the FCA there are a number of both early- and late-stage opportunities that have the potential to deliver value for our shareholders.